证券代码：688576 证券简称：西山科技 公告编号：2024-058 重庆西山科技股份有限公司 关于持续督导保荐机构主体变更的公告 2024 年 9 月 6 日 东方证券已于近日自证监会取得换发后的《经营证券期货业务许可证》，业 务范围含"证券承销与保荐"。东方证券与东方投行严格根据有关法律法规、证 监会批复及相关要求推进实施吸收合并工作，自 2024 年 9 月 2 日起，东方投行 存量客户与业务整体迁移并入东方证券，东方投行承接的投资银行业务项目均由 东方证券继续执行，东方投行对外签署的协议均由东方证券继续履行，东方投行 对外签署的协议均由东方证券继续履行，东方投行全部债权及债务由东方证券依 法承继。 公司持续督导保荐机构由东方投行变更为东方证券。 特此公告。 重庆西山科技股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重庆西山科技股份有限公司（以下简称"公司"）近日接到公司首次公开发 行股票之持续督导机构东方证券承销保荐有限公司（以下简称"东方投行"）的 通知，根据中国证券监督管理委员会于 20 ...

证券代码：688576 证券简称：西山科技 公告编号：2024-059 重庆西山科技股份有限公司 关于召开 2024 年半年度业绩说明会的公告 会议召开时间：2024 年 9 月 14 日（星期六）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 三、 参加人员 董事长、总经理：郭毅军 董事、财务总监、董事会秘书：白雪 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 说明会类型 重庆西山科技股份有限公司（以下简称"公司"）于 2024 年 8 月 31 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年半年度报告》。为便于广大 投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司计划于 2024 年 9 月 14 日（星期六）10:00-11:00 在"价值在线"（www.ir-online.cn）举 办重庆西山科技股份有限公司 2024 年半年度业绩说明会，与投资者进行沟通和 交流，广泛听取投资者的意见和建议 ...

证券代码：688576 证券简称：西山科技 公告编号：2024-057 重庆西山科技股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/6/18 | | --- | --- | | 回购方案实施期限 | 2024/6/28~2025/6/27 | | 预计回购金额 | 亿元 1 亿元~2 | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 股 3,351,952 | | 累计已回购股数占总股本比例 | 6.32% | | 累计已回购金额 | 19,882.73 万元 | | 实际回购价格区间 | 元/股~63.51 元/股 48.60 | 一、 回购股份的基本情况 2024 年 6 月 17 日，公司召开第三届董事会第二十六次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》。2024 ...

证券代码：688576 证券简称：西山科技 公告编号：2024-056 重庆西山科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 1,287,296 股。 本次股票上市流通总数为 1,287,296 股。 本次股票上市流通日期为 2024 年 9 月 18 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会《关于同意重庆西山科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕804 号）同意注册，重庆西山科技股份 有限公司（以下简称"公司"或"西山科技"）向社会公开发行人民币普通股 13,250,367 股，并于 2023 年 6 月 6 日在上海证券交易所科创板挂牌上市。公司首 次公开发行股票完成后，总股本为 53,001,466 股，其中有限售条件流通股为 41,133,405 股，占本公司发行后总股本的 77.6081%，无限售条件流通股为 11,868,061 ...

Financial Performance - The company reported a revenue of 500 million CNY for the first half of 2024, representing a 15% increase compared to the same period last year[9]. - The company has set a revenue guidance of 1.2 billion CNY for the full year 2024, indicating a projected growth of 10%[9]. - The company achieved operating revenue of 151.40 million RMB, a slight increase of 2.60% compared to the same period last year[15]. - Net profit attributable to shareholders increased by 28.25% year-on-year to 58.89 million RMB, primarily due to increased returns from cash management of idle funds[16]. - The net cash flow from operating activities decreased by 378.35%, mainly due to credit extended to distributors and increased payments for year-end bonuses, taxes, and raw material purchases[17]. - The company reported a total operating revenue of 151,404,503.49 CNY, an increase from 147,564,648.11 CNY in the same period of 2023, representing a growth of approximately 1.3%[119]. - The net profit for the first half of 2024 reached 58,894,600.71 CNY, compared to 45,922,917.01 CNY in the first half of 2023, indicating an increase of about 28.5%[121]. Research and Development - Research and development expenses increased by 30% to 50 million CNY, focusing on innovative surgical equipment[9]. - Research and development investment reached 23.01 million RMB, a year-on-year increase of 41.36%, reflecting greater investment in enhancing existing products and developing new ones[17]. - The proportion of R&D investment to operating revenue increased by 4.17 percentage points to 15.20%[16]. - The company reported a total R&D investment of 23.01 million yuan, a 41.36% increase compared to 16.28 million yuan in the same period last year[33]. - The company has established a comprehensive product R&D process, ensuring alignment with clinical needs and market trends[23]. - The company has a total of 135 R&D personnel, accounting for 21.33% of total employees, with 31.11% holding master's degrees or higher[46]. - The company has established national-level postdoctoral research stations, further strengthening its commitment to technological innovation and R&D investment[44]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[9]. - The company is positioned in the minimally invasive surgical tools sector, which is experiencing significant growth due to advancements in technology and materials[20]. - The company is focusing on innovation and domestic substitution in high-end medical devices, enhancing its competitive edge in the market[20]. - The company aims to expand the application of disposable tools in neurosurgery, orthopedics, ENT, and breast surgery, enhancing clinical coverage[35]. - The company has optimized its marketing channels and increased the promotion of endoscopic systems and energy surgical equipment, participating in various exhibitions and clinical trials to enhance product familiarity among end users[50]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[3]. - The company faces risks from intensified market competition, particularly in the surgical instrument sector, where brand differentiation and user experience are critical[52]. - The company is at risk of project halts or failures in new product development due to high investment and uncertainty in the medical device industry[52]. - The company is facing risks related to the implementation of centralized procurement policies, which may affect pricing and sales volumes[53]. - The company is at risk of product registration delays and potential regulatory challenges that could adversely affect its operations[53]. Corporate Governance and Compliance - No significant changes in corporate governance or management structure were reported during the period[3]. - The company has committed to strict compliance with medical device regulations to ensure product quality and safety throughout its operations[50]. - The company has established mechanisms for environmental protection and has been actively managing waste and emissions[65]. - The company has committed to measures to ensure effective use of raised funds and to prevent dilution of immediate returns[82]. Shareholder and Capital Structure - The company has committed to a share lock-up period of 36 months from the date of its IPO, during which no shares will be transferred or managed by the controlling shareholders[70]. - The actual controller and senior management have pledged not to transfer more than 25% of their shares annually during their tenure, with a similar restriction for four years post-IPO[70]. - The company has established a long-term commitment to resolve related party transactions and competition issues, ensuring compliance with relevant regulations[69]. - The company has received commitments from various stakeholders to uphold their shareholding restrictions, ensuring stability in ownership[68]. - The company has outlined specific penalties for any breaches of the share transfer commitments, including the requirement to return any profits gained from such breaches to the company[70]. Financial Position and Assets - The company has maintained a strong cash position with 200 million CNY in cash reserves as of June 30, 2024[9]. - The company reported a decrease in the use of right-of-use assets, with a value of 89.78 million and a reduction of 67.57% due to the upcoming use of self-built parks and short-term lease renewals[57]. - The company’s tax liabilities were reported at 469.71 million, down 68.91% as the corporate income tax for 2023 was paid during this period[57]. - The company’s total assets amounted to approximately $2.23 billion, a decrease of 4% from $2.32 billion at the end of 2023[118]. - The company’s cash and cash equivalents include CNY 599,806,513.02 in bank deposits, down from CNY 712,239,087.80 at the beginning of the period[181]. Investment and Future Outlook - The company is developing a 3D endoscope system to enhance image quality and provide stable image output, which is currently in the research phase[36]. - The company plans to use RMB 29,000 million of the raised funds for permanent working capital, accounting for 29.89% of the total raised funds of RMB 97,029.41 million[101]. - The company has made significant progress in digital transformation, completing the construction of PLM, MES, and CRM systems to achieve integrated digital operations[51]. - Future outlook includes continued investment in technology and potential mergers and acquisitions to drive growth[118].

证券代码：688576 证券简称：西山科技 公告编号：2024-055 重庆西山科技股份有限公司 二、公司前十大无限售条件股东持股情况 特此公告。 重庆西山科技股份有限公司董事会 关于回购股份事项前十大股东和前十大无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重庆西山科技股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日召开 第三届董事会第二十七次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，具体内容详见公司于 2024 年 8 月 28 日在上海证券交易所网 站（www.sse.com.cn）披露的《重庆西山科技股份有限公司关于以集中竞价交易 方式回购股份的预案》（公告编号：2024-049）及《重庆西山科技股份有限公司第 三届董事会第二十七次会议决议公告》（公告编号：2024-050）。 | | | 持股数量 | 占无限售 条件流通 | | --- | --- | --- | --- | | 序号 | 股东名称 | （股） | 股的比例 | | | ...

证券代码：688576 证券简称：西山科技 公告编号：2024-053 重庆西山科技股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》和《上海证券交易所科创板股票上市规则》等有关规定，重 庆西山科技股份有限公司（以下简称 "西山科技"或"公司"）就 2024 年半年 度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意重庆西山科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2023]804 号），公司首次向社会公开发行人 民币普通股 1,325.0367 万股，每股面值 1.00 元，每股发行价格 135.80 元。本 次公开发行募集资金总额为人民币 179,939.98 万元，实际募集资金净额为 ...

东方证券承销保荐有限公司 关于重庆西山科技股份有限公司 2024 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规 则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规的规定，东方证券承销保荐有限公司（以下简称"保荐机构"）作为重庆西 山科技股份有限公司（以下简称"西山科技"、"公司"）持续督导工作的保荐机 构，负责西山科技上市后的持续督导工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 | 序 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 号 | | | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体 的持续督导工作制定相应的工作计划 | 保荐机构已建立健全并有效执行了 | | | | 持续督导制度，并制定了相应的工作 | | | | 计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐机构已与西山科技签订承销与 | | | 与上市公司或相关当事人签署持续督导协议，明确双 | 保荐协议，该协议明确了双方在持续 | | | 方在持续督导期间的权利义务，并报 ...

重庆西山科技股份有限公司 章 程 2024 年 8 月 1 | 第一章 | 总 则 | 4 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 5 | | 第三章 | 股 份 | 5 | | 第一节 | 股份发行 | 5 | | 第二节 | 股份增减和回购 | 7 | | 第四章 | 股东和股东大会 | 9 | | 第一节 | 股东 | 9 | | 第二节 | 股东大会的一般规定 12 | | | 第三节 | 股东大会的召集 16 | | | 第四节 | 股东大会的提案与通知 17 | | | 第五节 | 股东大会的召开 19 | | | 第六节 | 股东大会的表决和决议 22 | | | 第五章 | 董事会 | 27 | | 第一节 | 董事 27 | | | 第二节 | 董事会 31 | | | 第六章 | 高级管理人员 | 37 | | 第七章 | 监事会 | 39 | | 第一节 | 监事 39 | | | 第二节 | 监事会 40 | | | 第八章 | 财务会计制度、利润分配和审计 | 41 | | 第一节 | 财务会计制度 41 | | | --- | --- | - ...